Horizon Kinetics Asset Management’s Alaunos Therapeutics TCRT Stock Holding History

Horizon Kinetics Asset Management’s Portfolio TCRT Stock Details TCRT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-227	Closed	-$2.4K	–	333
2023 Q4	$2.4K	Hold	227	–	–	﹤0.01%	325
2023 Q3	$4.48K	Hold	227	–	–	﹤0.01%	328
2023 Q2	$17.3K	Hold	227	–	–	﹤0.01%	330
2023 Q1	$21.4K	Hold	227	–	–	﹤0.01%	329
2022 Q4	$22.1K	Hold	227	–	–	﹤0.01%	317
2022 Q3	$58K	Hold	227	–	–	﹤0.01%	319
2022 Q2	$42K	Hold	227	–	–	﹤0.01%	330
2022 Q1	$22K	Hold	227	–	–	﹤0.01%	344
2021 Q4	$37K	Hold	227	–	–	﹤0.01%	349
2021 Q3	$62K	Hold	227	–	–	﹤0.01%	335
2021 Q2	$90K	Hold	227	–	–	﹤0.01%	339
2021 Q1	$122K	Buy	+227	New	+$141K	﹤0.01%	335

Other funds holding TCRT

MSD Partners New York $82.3M AUM 15.13% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

Commerce Bank Kansas City, Missouri $20.7B AUM 23.76% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

ACM

Allred Capital Management Dallas, Texas $275M AUM 18.19% 1-Year Est. Return

Horizon Kinetics Asset Management's TCRT Position: Q1 2024 in Review

Horizon Kinetics Asset Management sold out of Alaunos Therapeutics (TCRT) in Q1 2024, closing a stake of 227 shares — an estimated $2.4K sold.

Horizon Kinetics Asset Management first reported a position in TCRT in Q1 2021 and held it in 12 quarters. The position peaked at $122K in Q1 2021. 45 funds tracked by Wall St. Rank hold TCRT as of Q1 2024.

Horizon Kinetics Asset Management reported no remaining Alaunos Therapeutics position as of Q1 2024 after selling out during the quarter.
Horizon Kinetics Asset Management sold 227 Alaunos Therapeutics shares in Q1 2024, an estimated $2.4K.
Horizon Kinetics Asset Management first reported a position in Alaunos Therapeutics in Q1 2021 and held it in 12 quarters.
Horizon Kinetics Asset Management's Alaunos Therapeutics position peaked at $122K in Q1 2021.
45 funds tracked by Wall St. Rank held Alaunos Therapeutics as of Q1 2024.

Based on Horizon Kinetics Asset Management's 13F filing for Q1 2024, filed 14 May 2024.